Ac t i o n | 21 Jul 2026 05:00:00 ET │ 14 pages Ligand Pharmaceuticals (LGND.O) Resuming Coverage with Buy/H Rating and $387 TP Following Close of XOMA Acquisition Which Opens Up 100+ Shots On Goal CITI'S TAKE We resume coverage of LGND after a period of Rating Suspended with a Buy/H rating and $387 TP post-close of XOMA acquisition. We continue to see upside to current levels as the highly compelling acquisition of XOMA for $39/shr (~$739M equity value), plus a CVR tied to ongoing Tremfya litigation, was s ...